Skip to main content

Table 1 Clinical characteristics of simulated cohort

From: Health and economic impact of combining metformin with nateglinide to achieve glycemic control: Comparison of the lifetime costs of complications in the U.K

Parameter

Value

Age (years)

 

   Mean

58

   Range

29–88

Gender (% Female)

38%

Race

 

   Caucasian

92%

   Afro-Caribbean

4%

   Asian

4%

Initial resulting HbA1c level (mean)

 

   Metformin monotherapy

7.6%

   Combination therapy

6.9%

HbA1c annual upward drift

0.15%

Back to article page

Cost Effectiveness and Resource Allocation

ISSN: 1478-7547

Contact us